Inhibitors of protein biosynthesis. II. Mode of action of anisomycin.
D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D000963:Antimetabolites / Q000494:pharmacology*; D001798:Blood Proteins / Q000096:biosynthesis*; D002499:Centrifugation, Density Gradient; D004273:DNA, Neoplasm / Q000096:biosynthesis; D006367:HeLa Cells; D006454:Hemoglobins / Q000096:biosynthesis; D066298:In Vitro Techniques; D009363:Neoplasm Proteins / Q000096:biosynthesis*; D009374:Neoplasms, Experimental; D010452:Peptide Biosynthesis; D014176:Protein Biosynthesis; D011759:Pyrrolidines / Q000494:pharmacology*; D012343:RNA, Transfer / Q000378:metabolism; D011817:Rabbits; D012156:Reticulocytes / Q000166:cytology / Q000378:metabolism*; D012270:Ribosomes / Q000187:drug effects / Q000378:metabolism*; D012440:Saccharomyces / Q000166:cytology / Q000378:metabolism*
D000900:Anti-Bacterial Agents; D000963:Antimetabolites; D001798:Blood Proteins; D004273:DNA, Neoplasm; D006454:Hemoglobins; D009363:Neoplasm Proteins; D011759:Pyrrolidines; D012343:RNA, Transfer